Individualizing Care for Patients With Triple-Negative Breast Cancer

In this podcast episode from a live CCO Cancer Conversations webinar, Mark Pegram, MD, and Sara Tolaney, MD, MPH, provide expert perspectives on optimal treatment strategies for patients with triple-negative breast cancer (TNBC), with topics including:Current data and strategies for using PD-1/PD-L1 inhibitors in early-stage TNBC Clinical implications of PD-L1 status on therapeutic planning for patients with metastatic TNBC Current data and treatment strategies and the future of antibody–drug conjugates in the management of relapsed/refractory advanced TNBC Treatment implications of the presence of BRCA1/2 mutations and homologous recombination deficiency genes in advanced TNBCRole of PARP inhibitors in the treatment of TNBCPresenters: Mark Pegram, MDProfessor Medical OncologyStanford UniversityPalo Alto, CaliforniaSara Tolaney, MD, MPHAssociate Professor of MedicineDivision of Breast OncologyHarvard Medical SchoolChief, Division of Breast OncologyBreast Oncology ProgramDana-Farber Cancer InstituteBoston, MassachusettsContent based on an online CME/CE/CPE program supported by educational grants from Gilead Sciences, Inc.Link to full program:http://bit.ly/3iQzDz5

There are no comments yet.

Please log in to write the first comment.